2 models fit Privia Health Group Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Premium(i)Bronze42
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionPrivia Health Group Inc. Common Stock (PRVA)
Fair value (2 models)
$16.12
ACCE price target
$21.00
Rating
Overvalued
Horizon
12 months
Fair value published on 15 Oct 2026, 00:00 CEST; previously $15.82 since 10 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $22.41 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
39.0% above
-28.1% to fair value
ACCE score
53
out of 100
Analysts
94% buy
18 covering
P/E
109.0x
forward 17.3x
1-year return
-13.4%
Dividend yield
0.00%
Privia Health Group Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Privia Health runs physician enablement and value-based care: it manages independent physician practices, handling billing, contracting and data infrastructure, and earns a share of the shared savings those practices generate under Medicare and commercial risk contracts. Revenue grew 21.4%, and the forward P/E of 17.3 against a trailing 113.1 says earnings are expected to recover sharply from a thin base, with a 1.9% operating margin and 4.3% ROE leaving little room for error. The network model is the moat: once a practice is embedded in Privia's data and contracting platform, switching costs are real, but that same structure keeps margins low and exposes results to CMS rate changes and the timing of shared-savings settlements. The near-term question is whether operating leverage shows up as the network matures, which is what the forward multiple is pricing. At a 2.9B market cap and a score of 52/100, with no index membership, the name is a candidate for a deeper look on whether that margin ramp is credible, not a conclusion.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Insider selling with no buys
Insiders sold $12.19M across the last 10 disclosed transactions and bought $0.00M. Only 6.2% of shares are insider-held, so the selling is not trivial.
moderate
Price above model fair value
The stock trades 39.0% above the model fair value of $16.12, and 6.7% above the ACCE price target of $21.00.
moderate
Thin operating margin and high multiples
Operating margin is 1.9% and net margin 1.2%, while trailing P/E is 106.9 and EV/EBITDA 35.8. Earnings growth of 250% comes off a very low base.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 21.4% year over year, roughly in line with its five-year average pace of 21.0% a year.
Analysts rate the shares Buy or Strong Buy at 94%, with the analysts' mean price target sitting 37.2% above the current price.
The company carries almost no debt, with debt to equity at 0.01, and generated $162M of free cash flow over the last twelve months.
Why it could disappoint
The shares trade 39.0% above the model fair value of $16.12, and two of three valuation models in the consensus sit there.
Net margin of 1.2% and return on equity of 4.3% leave very little profit from each dollar of sales or shareholder capital.
The latest earnings per share missed expectations by 12.5%, coming in at 0.07 against 0.08 expected.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where PRVA's valuation models land
Price
$22.41
Model fair value
$16.12
Model range
$11.72 to $21.40
Fair value $16.12
Price $22.41
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores